Ventrus Biosciences, Inc. · New York, NY United States
| 787 7th Ave., 48th Fl. | Phone: 212-554-4300 |
| New York, NY | Fax: 212-554-4314 |
| 10019 | |
| United States | 
Map This Company |
Ventrus Biosciences, Inc. Rankings
Company Description
Ventrus Biosciences is developing drugs to make it easier for folks to sit, and then stay. The pharmaceutical company's product pipeline consists of three topical treatment candidates: an iferanserin ointment for hemorrhoids; a diltiazem cream for pain associated with anal fissures; and a phenylephrine gel for fecal incontinence. Ventrus is optimistic about its development efforts as there are no currently FDA-approved prescription products for the conditions it seeks to treat. Ventrus Biosciences filed to go public in mid-2010, but withdrew the IPO filing later that year.
Ventrus Biosciences, Inc. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | PrivateSingle Location |
|---|---|
| Fiscal Year-End | December |
| Employees | 2 |
Executives
6 executives listed for Ventrus Biosciences, Inc.'s New York, NY location.
| CEO, Chief Medical Officer, and Director | Russell Ellison | |
|---|---|---|
| CFO | David Barrett | |
| Director | Myron Holubiak |